{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:52:43Z","timestamp":1793857963476,"version":"4.6.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-025-03594-9","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:23:19Z","timestamp":1753881799000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prevalence, characteristics, and outcomes of patients with low baseline C-reactive protein in giant cell arteritis"],"prefix":"10.1186","volume":"27","author":[{"given":"Samuel","family":"Pichon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Koether","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Leurs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelien","family":"Chepy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Gachet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Sobanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Launay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hachulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"3594_CR1","doi-asserted-by":"publisher","unstructured":"Jennette JC. Overview of the 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Clin Exp Nephrol. 2013;17:603\u20136. https:\/\/doi.org\/10.1007\/s10157-013-0869-6.","DOI":"10.1007\/s10157-013-0869-6"},{"key":"3594_CR2","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/acr.24540","volume":"74","author":"MS Putman","year":"2022","unstructured":"Putman MS, Gribbons KB, Ponte C, et al. Clinicopathologic associations in a large international cohort of patients with giant cell arteritis. Arthritis Care Res. 2022;74:1013\u20138. https:\/\/doi.org\/10.1002\/acr.24540.","journal-title":"Arthritis Care Res"},{"key":"3594_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13075-023-03091-x","volume":"25","author":"T Penet","year":"2023","unstructured":"Penet T, Lambert M, Baillet C, et al. Giant cell arteritis-related cerebrovascular ischemic events: a French retrospective study of 271 patients, systematic review of the literature and meta-analysis. Arthritis Res Ther. 2023;25:116. https:\/\/doi.org\/10.1186\/s13075-023-03091-x.","journal-title":"Arthritis Res Ther"},{"key":"3594_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","volume":"79","author":"B Hellmich","year":"2020","unstructured":"Hellmich B, Agueda A, Monti S, et al. 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79:19\u201330. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215672.","journal-title":"Ann Rheum Dis"},{"key":"3594_CR5","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1002\/art.42325","volume":"74","author":"C Ponte","year":"2022","unstructured":"Ponte C, Grayson PC, Robson JC, et al. 2022 American college of rheumatology\/eular classification criteria for giant cell arteritis. Arthritis Rheumatol. 2022;74:1881\u20139. https:\/\/doi.org\/10.1002\/art.42325.","journal-title":"Arthritis Rheumatol"},{"key":"3594_CR6","doi-asserted-by":"publisher","unstructured":"Dejaco C, Ramiro S, Bond M, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. Ann Rheum Dis. 2023;ard\u20132023\u2013224543. https:\/\/doi.org\/10.1136\/ard-2023-224543.","DOI":"10.1136\/ard-2023-224543"},{"key":"3594_CR7","doi-asserted-by":"publisher","unstructured":"van der Geest, JAMA Intern Med, Sandovici KSM, Brouwer M, Mackie E et al. SL (2020) Diagnostic Accuracy of Symptoms, Physical Signs, and Laboratory Tests for Giant Cell Arteritis: A Systematic Review and Meta-analysis. JAMA Intern Med 180:1295. https:\/\/doi.org\/10.1001\/jamainternmed.2020.3050","DOI":"10.1001\/jamainternmed.2020.3050"},{"key":"3594_CR8","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1007\/s10067-020-05116-1","volume":"39","author":"P Martins","year":"2020","unstructured":"Martins P, Teixeira V, Teixeira FJ, et al. Giant cell arteritis with normal inflammatory markers: case report and review of the literature. Clin Rheumatol. 2020;39:3115\u201325. https:\/\/doi.org\/10.1007\/s10067-020-05116-1.","journal-title":"Clin Rheumatol"},{"key":"3594_CR9","doi-asserted-by":"crossref","unstructured":"Solans-Laque R, Fonseca E, Escalante B, et al. In: Vasculitis, editor. AB0697 giant cell arteritis with normal inflammatory markers at diagnosis. BMJ Publishing Group Ltd and European League Against Rheumatism; 2018. pp. 14901\u20131490.","DOI":"10.1136\/annrheumdis-2018-eular.7432"},{"key":"3594_CR10","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/art.1780341215","volume":"34","author":"CM Wise","year":"1991","unstructured":"Wise CM, Agudelo CA, Chmelewski WL, Mcknight KM. Temporal arteritis with low erythrocyte sedimentation rate: A review of five cases. Arthritis Rheum. 1991;34:1571\u20134. https:\/\/doi.org\/10.1002\/art.1780341215.","journal-title":"Arthritis Rheum"},{"key":"3594_CR11","doi-asserted-by":"publisher","unstructured":"Lopez-Diaz, Seminars in Arthritis and Rheumatism 2008, Llorca MJ, Gonzalez-Juanatey J et al. C, (2008) The Erythrocyte Sedimentation Rate Is Associated with the Development of Visual Complications in Biopsy-Proven Giant Cell Arteritis. Semin Arthritis Rheum 38:116\u2013123. https:\/\/doi.org\/10.1016\/j.semarthrit.2007.10.014","DOI":"10.1016\/j.semarthrit.2007.10.014"},{"key":"3594_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S, et al. Trial of Tocilizumab in Giant-Cell arteritis. N Engl J Med. 2017;377:317\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1613849.","journal-title":"N Engl J Med"},{"key":"3594_CR13","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1136\/ard-2022-223480","volume":"81","author":"C Ponte","year":"2022","unstructured":"Ponte C, Grayson PC, Robson JC, et al. 2022 American college of rheumatology\/eular classification criteria for giant cell arteritis. Ann Rheum Dis. 2022;81:1647\u201353. https:\/\/doi.org\/10.1136\/ard-2022-223480.","journal-title":"Ann Rheum Dis"},{"key":"3594_CR14","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1016\/S2665-9913(23)00101-7","volume":"5","author":"N Venhoff","year":"2023","unstructured":"Venhoff N, Schmidt WA, Bergner R, et al. Safety and efficacy of Secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Rheumatol. 2023;5:e341\u201350. https:\/\/doi.org\/10.1016\/S2665-9913(23)00101-7.","journal-title":"Lancet Rheumatol"},{"key":"3594_CR15","unstructured":"Romano J, D Kromrey J, Coraggio J, Skowronek J. Appropriate statistics for ordinal level data: should we really be using t-test and cohen\u2019. sd for evaluating group differences on the NSSE and other surveys; 2006."},{"key":"3594_CR16","doi-asserted-by":"crossref","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. 0 ed. Routledge; 2013.","DOI":"10.4324\/9780203771587"},{"key":"3594_CR17","unstructured":"Rea M, Parker LA. R (2014) Designing and Conducting Survey Research: A Comprehensive Guide, 4th Edition, Jossey-Bass."},{"key":"3594_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/sj.eye.6700240","volume":"17","author":"TRG Poole","year":"2003","unstructured":"Poole TRG, Graham EM, Lucas SB. Giant cell arteritis with a normal ESR and CRP. Eye. 2003;17:92\u20133. https:\/\/doi.org\/10.1038\/sj.eye.6700240.","journal-title":"Eye"},{"key":"3594_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.7861\/clinmed.22-4-s15","volume":"22","author":"MB Habib","year":"2022","unstructured":"Habib MB, Riaz A. Giant cell arteritis with normal inflammatory markers. Clin Med. 2022;22:15. https:\/\/doi.org\/10.7861\/clinmed.22-4-s15.","journal-title":"Clin Med"},{"key":"3594_CR20","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/j.1600-0420.2006.00864.x","volume":"85","author":"P Yu Wai Man","year":"2007","unstructured":"Yu Wai Man P, Dayan MR. Giant cell arteritis with normal inflammatory markers. Acta Ophthalmol Scand. 2007;85:460\u2013460. https:\/\/doi.org\/10.1111\/j.1600-0420.2006.00864.x.","journal-title":"Acta Ophthalmol Scand"},{"key":"3594_CR21","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/jama.287.1.92","volume":"287","author":"GW Smetana","year":"2002","unstructured":"Smetana GW. Does this patient have Temporal arteritis?? JAMA. 2002;287:92. https:\/\/doi.org\/10.1001\/jama.287.1.92.","journal-title":"JAMA"},{"key":"3594_CR22","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/j.1365-2796.1990.tb00158.x","volume":"227","author":"E Grodum","year":"1990","unstructured":"Grodum E, Petersen HA. Temporal arteritis with normal erythrocyte sedimentation rate. J Intern Med. 1990;227:279\u201380. https:\/\/doi.org\/10.1111\/j.1365-2796.1990.tb00158.x.","journal-title":"J Intern Med"},{"key":"3594_CR23","doi-asserted-by":"publisher","unstructured":"Jundt, Arthritis, Rheumatism, Mock JW et al. D (1991) Temporal arteritis with normal erythrocyte sedimentation rates presenting as occipital neuralgia. Arthritis Rheum 34:217\u2013219. https:\/\/doi.org\/10.1002\/art.1780340214","DOI":"10.1002\/art.1780340214"},{"key":"3594_CR24","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/0002-9343(86)90645-5","volume":"80","author":"RL Wong","year":"1986","unstructured":"Wong RL, Korn JH. Temporal arteritis without an elevated erythrocyte sedimentation rate. Am J Med. 1986;80:959\u201364. https:\/\/doi.org\/10.1016\/0002-9343(86)90645-5.","journal-title":"Am J Med"},{"key":"3594_CR25","doi-asserted-by":"publisher","unstructured":"Myklebust, Rheumatology, Gran G, STUDY OF 287 PATIENTS WITH POLYMYALGIA RHEUMATICA AND TEMPORAL ARTERITIS: CLINICAL AND LABORATORY MANIFESTATIONS AT ONSET OF DISEASE AND AT THE TIME OF DIAGNOSIS. JT (1996) A PROSPECTIVE. Rheumatology 35:1161\u20131168. https:\/\/doi.org\/10.1093\/rheumatology\/35.11.1161","DOI":"10.1093\/rheumatology\/35.11.1161"},{"key":"3594_CR26","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.semarthrit.2011.10.005","volume":"41","author":"TA Kermani","year":"2012","unstructured":"Kermani TA, Schmidt J, Crowson CS, et al. Utility of erythrocyte sedimentation rate and C-Reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum. 2012;41:866\u201371. https:\/\/doi.org\/10.1016\/j.semarthrit.2011.10.005.","journal-title":"Semin Arthritis Rheum"},{"key":"3594_CR27","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/art.40876","volume":"71","author":"JH Stone","year":"2019","unstructured":"Stone JH, Tuckwell K, Dimonaco S, et al. Glucocorticoid dosages and Acute-Phase reactant levels at giant cell arteritis flare in a randomized trial of Tocilizumab. Arthritis Rheumatol. 2019;71:1329\u201338. https:\/\/doi.org\/10.1002\/art.40876.","journal-title":"Arthritis Rheumatol"},{"key":"3594_CR28","doi-asserted-by":"publisher","unstructured":"Kermani JR, Warrington TA, Cuthbertson KJ et al. D, (2015) Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study. J Rheumatol 42:1213\u20131217. https:\/\/doi.org\/10.3899\/jrheum.141347","DOI":"10.3899\/jrheum.141347"},{"key":"3594_CR29","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1056\/NEJM199902113400607","volume":"340","author":"C Gabay","year":"1999","unstructured":"Gabay C, Kushner I. Acute-Phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448\u201354. https:\/\/doi.org\/10.1056\/NEJM199902113400607.","journal-title":"N Engl J Med"},{"key":"3594_CR30","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1042\/bj2650621","volume":"265","author":"PC Heinrich","year":"1990","unstructured":"Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990;265:621\u201336. https:\/\/doi.org\/10.1042\/bj2650621.","journal-title":"Biochem J"},{"key":"3594_CR31","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1002\/art.1780360913","volume":"36","author":"NE Roche","year":"1993","unstructured":"Roche NE, Fulbright JW, Wagner AD, et al. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum. 1993;36:1286\u201394. https:\/\/doi.org\/10.1002\/art.1780360913.","journal-title":"Arthritis Rheum"},{"key":"3594_CR32","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/1529-0131(200005)43:5<1041::AID-ANR12>3.0.CO;2-7","volume":"43","author":"CM Weyand","year":"2000","unstructured":"Weyand CM, Fulbright JW, Hunder GG, et al. Treatment of giant cell arteritis: Interleukin-6 as a biologic marker of disease activity. Arthritis Rheum. 2000;43:1041. https:\/\/doi.org\/10.1002\/1529-0131(200005)43:5<1041::AID-ANR12>3.0.CO;2-7.","journal-title":"Arthritis Rheum"},{"key":"3594_CR33","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1080\/03009740410009931","volume":"34","author":"JG Brun","year":"2005","unstructured":"Brun JG, Madland TM, Gran JT, Myklebust G. A longitudinal study of calprotectin in patients with polymyalgia rheumatica or Temporal arteritis: relation to disease activity. Scand J Rheumatol. 2005;34:125\u20138. https:\/\/doi.org\/10.1080\/03009740410009931.","journal-title":"Scand J Rheumatol"},{"key":"3594_CR34","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1093\/rheumatology\/kes294","volume":"52","author":"EM McCarthy","year":"2013","unstructured":"McCarthy EM, MacMullan PA, Al-Mudhaffer S, et al. Plasma fibrinogen is an accurate marker of disease activity in patients with polymyalgia rheumatica. Rheumatology. 2013;52:465\u201371. https:\/\/doi.org\/10.1093\/rheumatology\/kes294.","journal-title":"Rheumatology"},{"key":"3594_CR35","doi-asserted-by":"publisher","first-page":"1296393","DOI":"10.3389\/fmed.2023.1296393","volume":"10","author":"HK Skaug","year":"2023","unstructured":"Skaug HK, Fevang BT, Assmus J, et al. Giant cell arteritis: incidence and phenotypic distribution in Western Norway 2013\u20132020. Front Med. 2023;10:1296393. https:\/\/doi.org\/10.3389\/fmed.2023.1296393.","journal-title":"Front Med"},{"key":"3594_CR36","doi-asserted-by":"publisher","first-page":"105558","DOI":"10.1016\/j.jbspin.2023.105558","volume":"90","author":"SA Lyne","year":"2023","unstructured":"Lyne SA, Ruediger C, Lester S, et al. Clinical phenotype and complications of large vessel giant cell arteritis: A systematic review and meta-analysis. Joint Bone Spine. 2023;90:105558. https:\/\/doi.org\/10.1016\/j.jbspin.2023.105558.","journal-title":"Joint Bone Spine"},{"key":"3594_CR37","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s13075-024-03464-w","volume":"26","author":"J Narvaez","year":"2024","unstructured":"Narvaez J, Vidal-Montal P, S\u00e1nchez-Rodr\u00edguez I, et al. Comparative analysis of arterial involvement in predominant cranial and isolated extracranial phenotypes of giant cell arteritis using 18F-FDG PET-CT. Arthritis Res Ther. 2024;26:230. https:\/\/doi.org\/10.1186\/s13075-024-03464-w.","journal-title":"Arthritis Res Ther"},{"key":"3594_CR38","first-page":"57","volume":"117","author":"H de Boysson","year":"2019","unstructured":"de Boysson H, Liozon E, Ly KH, et al. The different clinical patterns of giant cell arteritis. Clin Exp Rheumatol 37 Suppl. 2019;117:57\u201360.","journal-title":"Clin Exp Rheumatol 37 Suppl"},{"key":"3594_CR39","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3899\/jrheum.140188","volume":"42","author":"AG Singh","year":"2015","unstructured":"Singh AG, Kermani TA, Crowson CS, et al. Visual manifestations in giant cell arteritis: trend over 5 decades in a population-based cohort. J Rheumatol. 2015;42:309\u201315. https:\/\/doi.org\/10.3899\/jrheum.140188.","journal-title":"J Rheumatol"},{"key":"3594_CR40","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.3899\/jrheum.151135","volume":"43","author":"E Liozon","year":"2016","unstructured":"Liozon E, Dalmay F, Lalloue F, et al. Risk factors for permanent visual loss in Biopsy-proven giant cell arteritis: A study of 339 patients. J Rheumatol. 2016;43:1393\u20139. https:\/\/doi.org\/10.3899\/jrheum.151135.","journal-title":"J Rheumatol"},{"key":"3594_CR41","doi-asserted-by":"publisher","first-page":"152020","DOI":"10.1016\/j.semarthrit.2022.152020","volume":"55","author":"S Parreau","year":"2022","unstructured":"Parreau S, Dumonteil S, Montoro FM, et al. Giant cell arteritis-related stroke in a large inception cohort: A comparative study. Semin Arthritis Rheum. 2022;55:152020. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152020.","journal-title":"Semin Arthritis Rheum"},{"key":"3594_CR42","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.semarthrit.2019.09.008","volume":"50","author":"A Dumont","year":"2020","unstructured":"Dumont A, Lecannuet A, Boutemy J, et al. Characteristics and outcomes of patients with ophthalmologic involvement in giant-cell arteritis: A case-control study. Semin Arthritis Rheum. 2020;50:335\u201341. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.09.008.","journal-title":"Semin Arthritis Rheum"},{"key":"3594_CR43","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.semarthrit.2019.02.011","volume":"49","author":"E Liozon","year":"2019","unstructured":"Liozon E, Delmas C, Dumonteil S, et al. Features and prognosis of giant cell arteritis in patients over 85 years of age: A case-control study. Semin Arthritis Rheum. 2019;49:288\u201395. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.02.011.","journal-title":"Semin Arthritis Rheum"},{"key":"3594_CR44","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1136\/ard-2023-223895","volume":"82","author":"S Monti","year":"2023","unstructured":"Monti S, Milanesi A, Klersy C, et al. Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients. Ann Rheum Dis. 2023;82:1098\u2013106. https:\/\/doi.org\/10.1136\/ard-2023-223895.","journal-title":"Ann Rheum Dis"},{"key":"3594_CR45","first-page":"182","volume":"74","author":"KDF Lensen","year":"2016","unstructured":"Lensen KDF, Voskuyl AE, Comans EFI, et al. Extracranial giant cell arteritis: A narrative review. Neth J Med. 2016;74:182\u201392.","journal-title":"Neth J Med"},{"key":"3594_CR46","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/art.22404","volume":"56","author":"K Maksimowicz-McKinnon","year":"2007","unstructured":"Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum. 2007;56:1000\u20139. https:\/\/doi.org\/10.1002\/art.22404.","journal-title":"Arthritis Rheum"},{"key":"3594_CR47","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/rheumatology\/kei245","volume":"45","author":"MC Park","year":"2006","unstructured":"Park MC, Lee SW, Park YB, et al. Post-interventional immunosuppressive treatment and vascular restenosis in takayasu\u2019s arteritis. Rheumatology. 2006;45:600\u20135. https:\/\/doi.org\/10.1093\/rheumatology\/kei245.","journal-title":"Rheumatology"},{"key":"3594_CR48","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"V Aboyans","year":"2018","unstructured":"Aboyans V, Ricco J-B, Bartelink M-LEL, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European society for vascular surgery (ESVS). Eur Heart J. 2018;39:763\u2013816. https:\/\/doi.org\/10.1093\/eurheartj\/ehx095.","journal-title":"Eur Heart J"},{"key":"3594_CR49","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/MD.0000000000000033","volume":"93","author":"MA Alba","year":"2014","unstructured":"Alba MA, Garc\u00eda-Mart\u00ednez A, Prieto-Gonz\u00e1lez S, et al. Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Med (Baltim). 2014;93:194\u2013201. https:\/\/doi.org\/10.1097\/MD.0000000000000033.","journal-title":"Med (Baltim)"},{"key":"3594_CR50","first-page":"S30","volume":"26","author":"G Nesher","year":"2008","unstructured":"Nesher G, Nesher R, Mates M, et al. Giant cell arteritis: intensity of the initial systemic inflammatory response and the course of the disease. Clin Exp Rheumatol. 2008;26:S30\u201334.","journal-title":"Clin Exp Rheumatol"},{"key":"3594_CR51","first-page":"171","volume":"19","author":"E Hachulla","year":"2001","unstructured":"Hachulla E, Boivin V, Pasturel-Michon U, et al. Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis. Clin Exp Rheumatol. 2001;19:171\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"3594_CR52","doi-asserted-by":"publisher","first-page":"105494","DOI":"10.1016\/j.jbspin.2022.105494","volume":"90","author":"L Moreel","year":"2023","unstructured":"Moreel L, Betrains A, Molenberghs G, et al. Epidemiology and predictors of relapse in giant cell arteritis: A systematic review and meta-analysis. Joint Bone Spine. 2023;90:105494. https:\/\/doi.org\/10.1016\/j.jbspin.2022.105494.","journal-title":"Joint Bone Spine"},{"key":"3594_CR53","doi-asserted-by":"publisher","first-page":"e002866","DOI":"10.1136\/rmdopen-2022-002866","volume":"9","author":"AK Hemmig","year":"2023","unstructured":"Hemmig AK, Aschwanden M, Seiler S, et al. Long delay from symptom onset to first consultation contributes to permanent vision loss in patients with giant cell arteritis: a cohort study. RMD Open. 2023;9:e002866. https:\/\/doi.org\/10.1136\/rmdopen-2022-002866.","journal-title":"RMD Open"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03594-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03594-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03594-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T08:02:28Z","timestamp":1753948948000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-025-03594-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3594"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03594-9","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"2 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"162"}}